23: A Novel Method to Reduce Rates of Extensive Chronic GvHD (cGvHD) without Increased Relapse for Cord Blood Transplant  by Chow, R. et al.
Oral Presentations 11isolated from the majority of donors and 1/3 of these recognized
a miH that was presented by a prevalent HLA allele and ex-
pressed on hematopoietic cells but not dermal fibroblasts. CTL
clones were isolated from these T cell lines and the polymorphic
genes encoding the novel miH were mapped by assessing recog-
nition of CEPH LCL transfected with the HLA restricting allele
and performing genetic linkage analysis and/or by cDNA library
screening. As most miH result from single nucleotide polymor-
phisms (SNP), we used the NCBI dbSNP database to access
SNP genotypes on a subset of the HapMap CEPH family mem-
bers and correlated the genotype with the miH phenotype to de-
rive a short list of candidate SNPs for the miH. We have
identified genes encoding five novel miHs so far and the tissue
expression of these genes is currently being evaluated. At least
one of the miH appears to be selectively expressed on hematopoi-
etic cells including leukemic stem cells and serves as a target for
effective T cell therapy of human leukemia in NOD/SCID mice.
Generation of miH specific CTL by primary in vitro stimulation
is an effective tool for accelerating the discovery of leukemia
associated miH.23
A NOVEL METHOD TO REDUCE RATES OF EXTENSIVE CHRONIC GVHD
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Post-thawwashing of frozenCB prior to transplantation is widely
practiced to remove DMSO, red cell debris and free hemoglobin,
however, washing a red cell containing product may result in cell
loss. We analyzed outcomes of engraftment, survival, relapse and
GvHD in 299 patients transplanted with plasma depleted but not
red cell reduced (PD) CB where 154 were washed (W) and 145ANC 500
& Plt 20 K
100 Day
TRM
1 & 3
Yr OS
1 &
3 Yr DFS
1 Yr
Relapse
Grade
II-IV/III-IV
aGvHD
Limited/
Extensive
cGvHD
Overall 88 ± 4/69 ± 4 17 ± 2 61 ± 3/56 ± 3 51 ± 3/39 ± 5 23 ± 3 35/14 20/11
W 87 ± 5/64 ± 5 17 ± 3 54 ± 4/48 ± 4 43 ± 5/30 ± 6 27 ± 5 36/15 9/17
NW 91 ± 6/76 ± 6 16 ± 3 69 ± 4/67 ± 4 60 ± 5/57 ± 5 20 ± 4 36/14 36/1
P value 0.002/0.001 0.05 0.02 0.05 0.29 0.93/0.80 \0.0001/
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All results are in % except for p-values & where indicated. Engraft-
ment presented as cumulative incidence. TRM, OS, DFS and
relapse rate estimated by Kaplan-Meier methods.were directly infused – (non-washed or NW). 207 (69%) of the
299 patients had malignant diagnosis. The two groups were com-
parable for patient, disease and graft characteristics except for
a higher % of Asian patients in the NW group in contrast to
a higher % of Caucasian/Hispanic patients, higher % of US
transplant centers and higher number of malignant diagnoses
for the W group. Nucleated cell recovery after thawing, as re-
ported by transplant centers, was higher for NW (median 85%
vs. 79%, p 5 0.003). The NW group had higher cumulative in-
cidences of and faster neutrophil (ANC500) and platelet engraft-
ment (Plt 20K and 50K) than the W group. No difference was
seen for acute GvHD (aGvHD); however, the NW group had
significantly lower rates of extensive cGvHD and higher rates of
limited cGvHD (p 5 0.0005 and \0.0001). Relapse rates were
similar between W and NW. Multivariate analysis and matched
pair analysis between W versus NW confirm these observations.
In univariate analysis, overall survival (OS) and disease-free sur-
vival (DFS) at 1 and 3 years were significantly higher for the
NW group. This retrospective analysis represents the largest se-
ries comparing different thaw methods for PD CB and is the first
to demonstrate a potential association of no post-thaw wash with
significant decrease in extensive cGvHD rate without concomi-
tant increase in relapse rate. These improvements may contribute
to the apparently better survival for the NW group. Prospective
trials which may include infusion of wash supernatants into
patients are necessary to confirm and better understand these
observations.24
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The initiation of graft versus host disease (GVHD) is dependent
upon donor T cell recognition of host alloantigens presented within
the context of host antigen presenting cells (APCs). Thereafter, host
APCs are replaced by donor APCs, however the role of donor APCs
in the propagation of GVHD remains largely unknown. Recently,
interleukin 23 has been identified as a cytokine that is secreted ex-
clusively by APCs (i.e. dendritic cells and macrophages) and has
been shown to play a major role in both local and systemic inflam-
matory responses. The purpose of these studies, therefore, was to
address this question by determining whether secretion of IL-23
by donor APCs played a role in either the local or systemic manifes-
tations of GVHD.Transplantation of bonemarrow and spleen cells
from IL-23 deficient C57BL/6 (B6)(H-2b) donors into lethally irra-
diated MHC-incompatible Balb/c (H-2d) or FVB (H-2q) mice re-
sulted in significantly reduced weight loss and proinflammatory
serum cytokine production, as well as improved splenic and thymic
reconstitution, when compared to animals transplanted with mar-
row grafts from normal B6 mice. Histological examination of
GVHD target tissues revealed that the reduction in the systemic
manifestations of GVHDwas accompanied by significantly reduced
pathological damage in the colon without any corresponding reduc-
tion in pathological scores in either lung or liver. To further under-
stand the role of IL-23 in colonic GVHD pathology, we examined
local proinflammatory cytokine production in colonic explant tis-
sues from both cohorts of mice. Transplantation with IL-23 defi-
cient marrow grafts was associated with significantly decreased
levels of IL-23, IFN-g, G-CSF, TNF-a, IL-1b and IL-6 in colonic
explant supernatants. Neither IL-12 nor IL-17 levels were altered
by the absence of donor-derived IL-23, providing evidence that
the proinflammatory effects of IL-23 in the colon occur indepen-
dently of these cytokines. Notably, levels of lipopolysaccharide
(LPS) which has been shown to have a vital role in the pathophysi-
ology of gut GVHDwere significantly decreased in both the serum
and in colonic explants from these animals. These data demonstrate
that IL-23 plays a unique role in the pathophysiology of GVHD of
the colon and is a proximate mediator in the cytokine cascade in-
duced by LPS translocation from the colon into the serum. These
